Molecular Biology of the Cell Sign up for new MBC in Press e-TOCs!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cuervo, A. M.
Right arrow Articles by Dice, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cuervo, A. M.
Right arrow Articles by Dice, J. F.

Vol. 9, Issue 8, 1995-2010, August 1998

Ikappa B Is a Substrate for a Selective Pathway of Lysosomal Proteolysis

Ana Maria Cuervo,*dagger Wei Hu,Dagger Bing Lim,dagger Dagger and J. Fred Dice*

 *Department of Physiology, Tufts University, School of Medicine, Boston, Massachusetts 02111; and  Dagger Department of Medicine, Harvard Institutes of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215

Submitted November 26, 1997; Accepted June 4, 1998
Monitoring Editor: Keith Yamamoto

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In lysosomes isolated from rat liver and spleen, a percentage of the intracellular inhibitor of the nuclear factor kappa  B (Ikappa B) can be detected in the lysosomal matrix where it is rapidly degraded. Levels of Ikappa B are significantly higher in a lysosomal subpopulation that is active in the direct uptake of specific cytosolic proteins. Ikappa B is directly transported into isolated lysosomes in a process that requires binding of Ikappa B to the heat shock protein of 73 kDa (hsc73), the cytosolic molecular chaperone involved in this pathway, and to the lysosomal glycoprotein of 96 kDa (lgp96), the receptor protein in the lysosomal membrane. Other substrates for this degradation pathway competitively inhibit Ikappa B uptake by lysosomes. Ubiquitination and phosphorylation of Ikappa B are not required for its targeting to lysosomes. The lysosomal degradation of Ikappa B is activated under conditions of nutrient deprivation. Thus, the half-life of a long-lived pool of Ikappa B is 4.4 d in serum-supplemented Chinese hamster ovary cells but only 0.9 d in serum-deprived Chinese hamster ovary cells. This increase in Ikappa B degradation can be completely blocked by lysosomal inhibitors. In Chinese hamster ovary cells exhibiting an increased activity of the hsc73-mediated lysosomal degradation pathway due to overexpression of lamp2, the human form of lgp96, the degradation of Ikappa B is increased. There are both short- and long-lived pools of Ikappa B, and it is the long-lived pool that is subjected to the selective lysosomal degradation pathway. In the presence of antioxidants, the half-life of the long-lived pool of Ikappa B is significantly increased. Thus, the production of intracellular reactive oxygen species during serum starvation may be one of the mechanisms mediating Ikappa B degradation in lysosomes. This selective pathway of lysosomal degradation of Ikappa B is physiologically important since prolonged serum deprivation results in an increase in the nuclear activity of nuclear factor kappa  B. In addition, the response of nuclear factor kappa  B to several stimuli increases when this lysosomal pathway of proteolysis is activated.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Transcription factors are the intermediates between receptor-mediated stimulation of the cell surface by hormones and growth factors and concomitant changes in cellular gene expression. One of the best-characterized transcription factors is the nuclear factor kappa  B (NF-kappa B),1 a heterodimeric protein with two subunits, p50 and p65. NF-kappa B is ubiquitously expressed and it regulates the expression of many genes (for review, see Baldwin, 1996). The best-characterized role of NF-kappa B is in the regulation of immune and inflammatory response genes (Verma et al., 1995). However, NF-kappa B also plays an important role in many other cellular processes such as cell proliferation and polarization (Weith et al., 1995), cell transformation and tumor growth (Higgins et al., 1993), programmed cell death (Beg et al., 1995), and synaptic plasticity, neurodegeneration, and neuronal development (O'Neill and Kaltschmidt, 1997). In response to various stimuli that include interleukin-1, tumor necrosis factors, bacterial and viral products, UV irradiation, and oxidative stress, NF-kappa B is released from the cytosol and translocates to the nucleus (reviewed in Baldwin, 1996). The cytosolic retention of NF-kappa B requires binding to inhibitor proteins known as inhibitor of the nuclear factor kappa B (Ikappa B) (reviewed in Verma et al., 1995). Seven mammalian Ikappa B molecules have been identified which differ in their inhibitory specificity for different members of the NF-kappa B family. The best-characterized Ikappa B is Ikappa Balpha that inhibits complexes containing p65/p50 (Scott et al., 1993).

Under most of the conditions analyzed, degradation of Ikappa B requires phosphorylation and ubiquitination at its amino terminal region, followed by proteolysis by the 26S proteasome (Alkalay et al., 1995; Scherer et al., 1995). However, there are several circumstances in which participation of other protein degradation systems have been described. Thus, the calcium-activated calpain system is responsible for Ikappa B degradation after silica-induced NF-kappa B activation (Chen et al., 1997) and for basal degradation of Ikappa B in immature B cells (Miyamoto et al., 1998). Other proteolytic systems, the caspases, which are involved in the apoptotic process, can also be involved in Ikappa B degradation in certain transformed cells (White and Gilmore, 1996), and an unphosphorylated form of Ikappa Bbeta is degraded in the nucleus by an unknown proteinase which is not sensitive to proteasome inhibitors (Suyang et al., 1996). In addition, in pre-B cells degradation of Ikappa B does not require phosphorylation and ubiquitination steps (Baeuerle and Baltimore, 1996). An Ikappa B QL-rich region seems to be important in inducible degradation of Ikappa B by the proteasome (Sun et al., 1996). Signal sequences for protein instability (PEST sequences) identified in the Ikappa B carboxyl-terminal region have been proposed to be important for Ikappa B degradation in unstimulated cells (van Antwerp and Verma, 1996) without participation of the 26S proteasome. These findings suggest that degradation of Ikappa B can be by different pathways depending on the type of cell and the kind of stimulus applied.

In preliminary experiments in which a lysosomal membrane protein (Adra et al., 1996) was overexpressed in several cell lines, we found an activation and nuclear translocation of NF-kappa B (Hu and Lim, unpublished results). This led us to question whether lysosomes may be involved in Ikappa B degradation. In the present study, we have investigated the possible participation of lysosomes in Ikappa B degradation under different cellular conditions. In addition to the continuous lysosomal degradation of complete portions of cytosol, including organelles and soluble proteins, by a mechanism known as macroautophagy (Dunn, 1994), a selective degradation of cytosolic proteins in lysosomes has also been described (reviewed in Dice et al., 1990; Cuervo et al., 1997). Transport of specific cytosolic proteins into lysosomes requires the presence of a consensus peptide motif in the substrate protein biochemically related to the pentapeptide KFERQ (Chiang and Dice, 1988). A cytosolic chaperone of 73 kDa (hsc73) binds to the substrate proteins at the region containing the motif sequence, and this binding of hsc73 stimulates the direct transport of substrate proteins into lysosomes (Chiang et al., 1989; Terlecky et al., 1992). A second chaperone located within the lysosomal lumen (lysosomal hsc73) is also necessary for the selective uptake of substrate proteins (Agarraberes et al., 1997; Cuervo et al., 1997). An integral lysosomal membrane protein of 96 kDa (lgp96) acts as the receptor for the hsc73-mediated lysosomal degradation pathway (Cuervo and Dice, 1996). This selective lysosomal degradation is activated in conditions of serum deprivation in cultured cells (Neff et al., 1981) or long-term starvation in animals (Wing et al., 1991; Cuervo et al., 1995a), and shows a clear tissue-dependent activity (Wing et al., 1991). Approximately 30% of the total cytosolic proteins contain the KFERQ-related motif and are, therefore, putative substrates for this lysosomal pathway of degradation (Dice, 1990). The proteins experimentally identified as substrates include RNase A (Neff et al., 1981; McElligott et al., 1985), GAPDH (Aniento et al., 1993), aldolase (Aniento et al., 1993), components of other proteolytic systems such as some subunits of the 20S proteasome (Cuervo et al., 1995b), lipid-binding proteins such as annexins II, IV, and VI (Cuervo, Barnes, and Dice, unpublished results), a cytosolic form of alpha 2-microglobulin (Cuervo, Hildebrand, Bomhard, and Dice, unpublished results), and the c-fos transcription factor (Aniento et al., 1996).

Here, we show that Ikappa B is directly transported into lysosomes by the above-described hsc73-mediated pathway. This pathway of proteolysis can reduce intracellular levels of Ikappa B and cause activation of NF-kappa B. Furthermore, when this selective lysosomal pathway of proteolysis is activated, the activity of NF-kappa B is more easily stimulated by diverse agents.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Animals and Cells

Male Wistar rats of 200-250 g body weight were starved for 20 h before each experiment. Chinese hamster ovary (CHO) cells (American Type Culture Collection, Rockville, MD) were grown in 100-mm diameter round plates or 250 mm per side square plates until confluent in F-12 medium (Life Technologies, Gaithersburg, MD) containing 10% newborn calf serum (NCS) and antibiotics (penicillin/streptomycin) (Neff et al., 1981). WEHI231 cells lines stably transfected with and expressing a hemagglutinin (HA; amino acid 98-108 of the influenza protein) epitope-tagged SS32/36AA mutant Ikappa Balpha were kindly provided by Dr. S. Miyamoto (Department of Human Oncology, University of Wisconsin, Madison, WI). These cells were maintained in RPMI 1640 (Mediatech, Asheville, NC) supplemented with 10% FBS, 5 × 10-5 M beta -mercaptoethanol, and 500 µg/ml hygromycin. To deprive cells of serum, plates were extensively washed with HBSS (Life Technologies), and fresh medium not containing serum was added.

Chemicals and Antibodies

Sources of reagents and antibodies were as previously described (Terlecky and Dice, 1993; Cuervo et al., 1994; Adra et al., 1996; Cuervo et al., 1997). IL-1beta (IL-1) was purchased from Oncogene (Cambridge, MA). Lipopolysaccharide (LPS), tumor necrosis factor alpha  (TNF-alpha ), phorbol 12-myristate 13-acetate (PMA), and pyrrolidine dithiocarbamate (PDTC) were purchased from Sigma (St. Louis, MO). The calf intestinal alkaline phosphatase was from Life Technologies. Polyclonal antibodies against Ikappa Balpha and beta , p65 and p50, were obtained from Santa Cruz Biotechnology (Santa Cruz, CA), and the mAb against conjugated ubiquitin was purchased from Zymed (South San Francisco, CA). The mAb (12CA5) against the amino acids 98-108 of the HA protein was from Dr. F. McKeon (Department of Cell Biology, Harvard Medical School, Boston, MA). The polyclonal antibody against the cytosolic region of lgp96 was prepared in our laboratory (Cuervo and Dice, 1996). The polyclonal antibody against the nuclear factor of activated T cells 1 was a gift from Dr. A. Rao (Department of Pathology, Harvard Medical School, Boston, MA). The plasmid containing the fusion protein GST-Ikappa Balpha was kindly provided by Dr. S. Ghosh (Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT).

Stable Cellular Transfection

Cells were transfected using the calcium phosphate method (Maniatis et al., 1982). The cDNA for human lamp2 (Fukuda et al., 1988) was subcloned in the pCR3 mammalian expression vector (Invitrogen, San Diego, CA). Selection of transfected cells was performed by resistance to Geneticin (400 µg/ml; Life Technologies) for at least 15 d. Individual colonies were grown in 48-well plates in the presence of the antibiotic for another 7 d. Expression of the protein was verified by immunofluorescence of fixed cells and immunoblot of cellular lysates after separation by SDS-PAGE.

Isolation of Subcellular Fractions

Spleen and liver from previously starved rats were homogenized in 0.25 M sucrose. Subcellular fractions were prepared by differential centrifugation and further centrifugation in a density gradient of metrizamide as described previously (Cuervo et al., 1995; Adra et al., 1996). Lysosomal matrix and membranes were obtained as described previously (Ohsumi et al., 1983). Briefly, lysosomes were pelleted and resuspended in a hypotonic solution (0.025 M sucrose) for 30 min at 0°C. Lysosomal membranes were sedimented by centrifugation at 105,000 × g for 30 min, and the supernatant corresponding to the lysosomal matrix was also separately recovered. In some experiments, two different groups of lysosomes with different contents of hsc73 were isolated as previously described (Cuervo et al., 1997). Lysosomes from cultured cells were isolated as described by Storrie and Madden (1990). In all of the experiments, lysosomal integrity was verified after isolation and at the end of the incubation period by measuring the activity of beta -hexosaminidase, a lysosomal enzyme, in the incubation medium (Storrie and Madden, 1990). Experiments with more than 10% broken lysosomes were discarded.

Proteolysis Measurements

Degradation of the Ikappa B already located in the lysosomal matrix was measured by incubation of intact lysosomes (50 µg of protein) in 10 mM MOPS/0.25 M sucrose/5 mM DTT (pH 7.2) at 37°C. At selected times aliquots were removed, separated by SDS-PAGE, and the remaining Ikappa B inside lysosomes was detected by immunoblot. Lysosomal degradation of exogenously added proteins was assayed by incubation of intact lysosomes in the above medium with GAPDH radiolabeled by reductive methylation (Jentoft and Dearborn, 1983) ([14C]GAPDH; 1.2 × 106 dpm/nmol), a pool of cytosolic proteins from human fibroblasts, or GST-Ikappa B metabolically labeled with [3H]leucine or [35S]methionine/cysteine, respectively ([3H]proteins, 2.0 × 106 dpm/µg; [35S]GST-Ikappa B, 7.3 × 106 dpm/nmol). Reactions were stopped with a final concentration of 10% trichloroacetic acid and, after filtration in the Millipore Multiscreen Assay System (Millipore, Bedford, MA) with a 0.45-µm pore membrane, radioactivity in the flow-through was measured in a 2100TR Packard liquid scintillation analyzer (Packard Instruments, Meriden, CT). Proteolysis was expressed as the percentage of the initial acid-precipitable radioactivity transformed to acid-soluble radioactivity during the incubation time.

Uptake of Proteins by Lysosomes

Transport of proteins into isolated lysosomes was analyzed using a previously described in vitro system (Terlecky and Dice, 1993; Cuervo et al., 1994). Briefly, lysosomal proteolytic activity was inhibited by treatment of freshly isolated lysosomes with 100 µM chymostatin for 10 min at 0°C. After dilution in two volumes of 10 mM MOPS/0.25 M sucrose (pH 7.2) buffer, lysosomes were incubated with GST-Ikappa B (5 µg) for 20 min at 37°C. At the end of the incubation, the protein remaining outside lysosomes was removed by treatment with proteinase K (3 µg) at 0°C for 10 min. Lysosomes were recovered by centrifugation and subjected to SDS-PAGE. GST-Ikappa B transported into lysosomes was detected by immunoblot after SDS-PAGE. Where indicated GST-Ikappa B was previously incubated with calf intestinal alkaline phosphatase (40 U) in 50 mM Tris-HCl/0.1 mM EDTA/0.3 M NaCl/0.1 mM MgCl2/10 µM ZnCl2 (pH 8.5) for 1 h at 37°C.

Determination of Ikappa B Half-Life

CHO cells at 60-70% confluency were radiolabeled with an [35S]methionine/cysteine mixture (0.2 mCi/ml) for 48 h in medium supplemented with 10% NCS. In some experiments the incubation lasted only 2 h to preferentially label short-lived proteins. After extensive washing, cells were maintained in the presence of 10% NCS (serum+) or in medium without serum (serum-). Where indicated, NH4Cl was added to a final concentration of 15 mM. In some experiments PDTC or H2O2 was added at the indicated concentrations in the fresh medium immediately after the labeling. At increasing times cells were lysed in lysis buffer [50 mM Tris-HCl (pH 8)/150 mM NaCl/1% Nonidet-P40/0.5% sodium deoxycholate/0.1% SDS]. Lysates were cleared by centrifugation, and supernatants were incubated with specific antibodies against Ikappa B or p65 previously conjugated to protein A-Sepharose beads. After extensive washing with lysis buffer, the immunoprecipitate was subjected to SDS-PAGE. Gels were exposed to a PhosphorImager screen and the immunoprecipitated Ikappa B or p65 was quantified with a PhosphorImager system (Molecular Dynamics, Sunnyvale, CA). The half-life of the protein was calculated from the formula t1/2 = ln2/degradation rate.

Electromobility Gel Shift Assay

Nuclear extracts from CHO cells were prepared as follows. Cells (1.5 × 107) were grown until confluent in medium supplemented with 10% NCS and then, after extensive washing, the medium was replaced with fresh medium with or without serum as indicated. After 16 h (except where indicated) cells were harvested, washed, and resuspended in hypotonic buffer [10 mM Tris-HCl (pH 7.4)/10 mM NaCl/30 mM MgCl2/0.02% sodium azide] with a broad range of proteinase inhibitors (0.1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride, 100 µM leupeptin, 1 µM pepstatin A, 1 mM EDTA, and 0.01% sodium azide). After 10 min at 0°C, 0.05% of Nonidet P-40 was added, and nuclei were pelleted by centrifugation at 2500 × g for 5 min. Pellets were washed with the same buffer and resuspended in 20 mM HEPES (pH 7.4)/420 mM NaCl/1.5 mM MgCl2/0.2 mM EDTA/25% glycerol/0.01% sodium azide with proteinase inhibitors for 30 min. After centrifugation at 12,000 × g for 10 min, nuclear proteins were recovered in the supernatant and stored at -70°C. A double-stranded oligonucleotide containing the immunoglobulin kappa  enhancer kB site of NF-kappa B (CAGAGGGGACTTTCCGAGA) was end labeled with T4 polynucleotide kinase in the presence of 20 µCi of [gamma -32P]ATP. Binding assays were performed by incubation of nuclear proteins (5 µg) with the radiolabeled probe (10,000 dpm) and 0.5 µg of poly(dI-dT) in 8.5 mM HEPES (pH 7)/ 104 mM NaCl/0.2 mM DTT/8.5% glycerol for 20 min at 25°C. Samples were subjected to electrophoresis in a 4% nondenaturing polyacrylamide gel. After drying, the gel was exposed to a PhosphorImager screen. In some experiments, nuclear transport of NF-kappa B was induced by addition of PMA, LPS, IL-1, TNF-alpha , or H2O2 at the indicated concentrations in the culture medium 4 h prior to cell harvesting. The specificity of the binding to NF-kappa B in the nuclear extracts was determined by competition in the presence of a 200-fold excess of unlabeled oligonucleotide probe.

General Methods

SDS-PAGE (Laemmli, 1970), immunoblotting (Towbin et al., 1979), and fluorography (Bonner and Laskey, 1974) were performed by standard procedures. Protein concentration in samples was measured according to the Lowry et al. (1951) method using BSA as a standard. Hsc73 was purified from rat liver by affinity chromatography using an ATP-agarose matrix (Welch and Feramisco, 1985). GST-Ikappa B was isolated from Escherichia coli previously transformed with the above-mentioned vector and after induction with 1 mM isopropyl-beta -D-thiogalactopyranoside for 4 h (Maniatis et al., 1982). The GST-Ikappa B was purified with a glutathione-agarose column. Densitometric analyses were performed with an Image Analyzer System (Inotech S-100, Sunnyvale, CA).

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Immunolocalization of Ikappa B in Lysosomes

As a first step toward determining whether lysosomes were involved in the intracellular degradation of Ikappa B, we analyzed whether or not Ikappa B could be detected in the lysosomal fraction. As shown in Figure 1, A and B, most of the intracellular Ikappa B alpha  and beta  is located in the cytosol. Both proteins also associate to some extent with microsomes but are not detected in mitochondria. In lysosomes it is possible to detect Ikappa B alpha  and beta  which account for 1.5% and 1.0% of the Ikappa B in spleen homogenate, respectively, when corrected for lysosomal recovery. A portion of the lysosome-associated Ikappa B (30-42%) is located at the lysosomal membrane, probably bound to its cytosolic surface, but the remaining Ikappa B is within the lysosomal matrix. Only slight differences were found in the lysosomal content of Ikappa B alpha  and beta . The presence of Ikappa B in lysosomes is not the result of a cytosolic contamination in the process of isolation since the mitochondrial fraction, obtained by similar methods, does not show detectable levels of Ikappa B. In addition, no detectable levels of two other transcriptional factors (p65 of NF-kappa B and NFAT-1) were evident in the lysosomes (Figure 1, C and D).


View larger version (56K):
[in this window]
[in a new window]
 
Figure 1.   A portion of intracellular Ikappa B is located in lysosomes. Rat spleens were fractionated after homogenization as described in MATERIALS AND METHODS. After the isolation, part of the lysosomal fraction was subjected to hypotonic shock, and lysosomal membranes and matrix were separated by centrifugation. The same amount of protein (100 µg) of the indicated fractions (and the membrane and matrix derived from 100 µg of lysosomal protein) was then subjected to SDS-PAGE and immunoblotted with specific antibodies against Ikappa B alpha  (A), Ikappa B beta  (B), p65 (C), or nuclear factor of activated T cells 1 (NFAT, D). HOM, homogenate; CYT, cytosol; MIC, microsomes; MIT, mitochondria; LYS, lysosomes; MB, membrane; MTX, matrix.

Lysosomal Degradation of Ikappa B

The lysosome-associated Ikappa B can be readily degraded once inside the lysosomal matrix. Thus, when liver lysosomes were incubated in an isotonic medium to maintain lysosomal integrity and levels of Ikappa B associated with lysosomes were analyzed by immunoblot (Figure 2A), the lysosomal content of Ikappa B decreased with the incubation time, and this decrease was slowed in the presence of leupeptin, an inhibitor of cathepsin B, H, and L (Salvelsen and Nagase, 1989). Quantification of four immunoblots similar to the ones shown revealed that the half-life of Ikappa B alpha  and beta  once inside lysosomes was approximately 20 min. Since Ikappa Balpha and beta  behaved similarly in these initial studies, we chose to analyze further only Ikappa Balpha .


View larger version (37K):
[in this window]
[in a new window]
 
Figure 2.   Degradation of Ikappa B inside lysosomes. (A) Rat liver lysosomes were incubated in an isotonic medium at 37°C in the absence or presence (+Leup) of leupeptin. At the indicated times, reactions were stopped by addition of Laemmli sample buffer and levels of Ikappa B alpha  and beta  present in the lysosomal fraction were detected by immunoblot following SDS-PAGE. The graph shows the quantification of four different experiments similar to the one shown and the calculated half-life for both proteins. (B) Lysosomes isolated from liver of nontreated or leupeptin-treated rats (see MATERIALS AND METHODS) were subjected to hypotonic shock and matrix and membranes were separated. Levels of Ikappa B in each lysosomal fraction were detected by immunoblot with a specific antibody following SDS-PAGE.

To estimate degradation rates of Ikappa B that could be attributed to lysosomes in vivo, we compared lysosomal levels of this protein in control rats and in rats previously treated with leupeptin for 1 h to partially inhibit the lysosomal proteolytic activity. As shown in Figure 2B, after leupeptin treatment, there is a significant increase in lysosome-associated Ikappa B (52% more than in untreated animals), and this increase is mainly detected in the lysosomal matrix. On the basis of these results and the above-mentioned half-life of Ikappa B once inside the lysosomal matrix, we calculated that in starved rats approximately 0.4% of the total intracellular content of Ikappa B is transported into lysosomes per hour. Notice that the final value has been corrected for the percentage of lysosomal recovery in the isolation.

Pathway for Lysosomal Uptake of Ikappa B

The significant differences between the lysosomal amount of Ikappa B and that of other transcription factors could be related to their different proteolytic susceptibility once inside lysosomes. However, experiments with broken lysosomes revealed that half-lives of Ikappa B and NF-kappa B were similar once in contact with the lysosomal proteinases (approximately 15 min; our unpublished results). These results suggest that the transport of Ikappa B into lysosomes is selective and preferred over other cytosolic proteins. To determine whether Ikappa B could be entering lysosomes through the hsc73-mediated pathway, we isolated two lysosomal populations with very different activities for the hsc73-mediated transport (Cuervo et al., 1997a). The major difference between these groups of lysosomes is their different content of hsc73, a necessary factor for substrate protein uptake (Agarraberes et al., 1997; Cuervo et al., 1997a; Figure 3, top). As shown in Figure 3 (middle), levels of Ikappa B in the lysosomal population active in the direct transport pathway were significantly higher than in the less active population. As a control, levels of hexokinase, a cytosolic protein that has been reported to not follow the selective pathway for its transport to lysosomes (Cuervo et al., 1997a), were similar in both groups (Figure 3, bottom). These results suggest that Ikappa B might be a substrate for the selective lysosomal pathway of protein degradation.


View larger version (43K):
[in this window]
[in a new window]
 
Figure 3.   Distribution of hsc73, Ikappa B, and hexokinase in different lysosomal populations. Two different lysosomal populations were isolated from rat liver as described in MATERIALS AND METHODS. The same amounts of protein (100 µg) of each lysosomal group (HSC+ and HSC-) and the cytosolic fraction were subjected to SDS-PAGE and immunoblotted with specific antibodies for hsc73 (top), Ikappa Balpha (middle), and hexokinase (HEXK, bottom).

We used isolated lysosomes to analyze a possible direct uptake of Ikappa B (Terlecky and Dice, 1993; Cuervo et al., 1994). Lysosomes from rat spleen (Figure 4A, right) or liver (Figure 4A, left) were incubated with the radiolabeled fusion protein GST-Ikappa B to differentiate it by size from the Ikappa B already present in the lysosomal matrix. When lysosomes were sedimented after the incubation, part of GST-Ikappa B was associated with lysosomes. Some of this protein was resistant to proteinase treatment and therefore was located in the lysosomal matrix. These results suggest that GST-Ikappa B can be transported in vitro into lysosomes.


View larger version (54K):
[in this window]
[in a new window]
 
Figure 4.   Ikappa B and the hsc73-mediated pathway for protein degradation. (A) Direct uptake of Ikappa B by lysosomes. The fusion protein GST-Ikappa B (5 µg) was incubated with intact rat liver and spleen lysosomes (100 µg of protein) under standard conditions. At the end of the incubation, proteinase K (5 µg) was added to part of the samples, as indicated, and samples were subjected to SDS-PAGE and immunoblotted for Ikappa B. (B) Effect of different proteins on Ikappa B uptake by lysosomes. Ikappa B was incubated under standard conditions with rat liver lysosomes without additions or in the presence of equimolar amounts of the indicated proteins. (C) Effect of blockage of lgp96 on Ikappa B lysosomal uptake. Rat liver lysosomes were preincubated with a specific antibody against lgp96 (lane 3) or with preimmune serum (lane 4). In B and C uptake of Ikappa B was assayed as described in A by adding proteinase K to all of the samples. (D) Binding of hsc73 to Ikappa B. Hsc73 from rat liver was incubated with GST-Ikappa B with the indicated additions for 1 h at 37°C. At the end of the incubation, the sample was subjected to affinity chromatography with glutathione immobilized on agarose beads. Levels of hsc73 associated with GST-Ikappa B or to the beads alone were detected after SDS-PAGE by immunoblot with a specific antibody against hsc73. GST-Ikappa B (1 µg) is in lane 1 in A-C. Hsc73 (0.5 µg) is in lane 1 in D. (E) Coimmunoprecipitation of Ikappa B and hsc73 in CHO cells. CHO cells maintained in the presence or absence of serum for 12 h (as labeled) were subjected to immunoprecipitation with a specific antibody against Ikappa B. Total cellular extracts (ce) and immunoprecipitates (ip) were analyzed by SDS-PAGE and immunoblot for the presence of hsc73 (lanes 1-4) and p65 (lanes 5-8). (F) Association of Ikappa B proteins at the lysosomal membrane. Lysosomes isolated from rat liver were subjected to immunoprecipitation with specific antibodies against hsc73 (lane 1), Ikappa B (lanes 2 and 4), or lgp96 (lane 3). Levels of hsc73 (lanes 1 and 2) or lgp96 (lanes 3 and 4) in the immunoprecipitates were analyzed as in E.

These transport experiments were performed without addition of exogenous hsc73, because we have previously demonstrated that the levels of hsc73 associated with the membrane of rat liver lysosomes are sufficient to mediate the transport of substrate proteins into the lysosomal matrix (Cuervo et al., 1994). In addition, when 35S-labeled Ikappa B was incubated with intact lysosomes from CHO cells with low levels of membrane-associated hsc73, a clear dependence on hsc73 and ATP for the uptake and degradation of Ikappa B was observed (see below).

To determine whether the transport system used by Ikappa B was the hsc73-mediated pathway previously described, or at least whether Ikappa B shared some of the components of this system for its transport into lysosomes, we analyzed the effect of different substrates (RNase A, GAPDH) and nonsubstrate proteins (ovalbumin) on the Ikappa B lysosomal uptake. After incubation, all samples were treated with proteinase K to detect the amount of protein transported into the lysosomal matrix. As shown in Figure 4B, in the presence of two of the substrates for the hsc73-mediated transport, the amount of Ikappa B transported into lysosomes significantly decreased. However, addition of ovalbumin in the incubation medium did not modify Ikappa B uptake. In addition, when lgp96, the receptor protein at the surface of the lysosomes for the specific substrates was previously blocked with a specific antibody, a decrease in the uptake of Ikappa B was also observed. Incubation of lysosomes with a preimmune serum did not significantly modify levels of Ikappa B uptake (Figure 4C).

Finally, another characteristic of the cytosolic proteins that can be directly transported into lysosomes is their ability to bind to hsc73, a molecular chaperone. This binding is nucleotide dependent because ADP is required for substrate binding and ATP is necessary for substrate release. A consensus motif for binding to hsc73 has been previously identified in substrates for this pathway (Dice, 1990). Analysis of the Ikappa B sequence revealed the presence of a region biochemically related with the proposed pentapeptide (VKELQ amino acids 46-50). When GST-Ikappa B was incubated with hsc73 and the fusion protein was recovered by affinity binding to GST-agarose beads, part of the hsc73 was also recovered (Figure 4D). Levels of hsc73 recovered in the presence of ATP were significantly lower. Most hsc73 bound directly to the GST-Ikappa B, since in the absence of GST-Ikappa B hsc73 was hardly detected (Figure 4D, lane 4). No binding of hsc73 occurred to GST itself (our unpublished results). This interaction of Ikappa B with hsc73 was also detected in vivo. Using a specific antibody against Ikappa B, we were able to coimmunoprecipitate hsc73 from cytosolic extracts of CHO cells (Figure 4E, lane 3). Interestingly, after serum removal cytosolic levels of hsc73 remain constant (Figure 4E, lane 2) but the amount of hsc73 coprecipitated with Ikappa B was significantly higher (12-fold increase; Figure 4E, lane 4). As shown in Figure 4E, lanes 7 and 8, the amount of NF-kappa B coprecipitated with Ikappa B remained unchanged at this early point of serum deprivation. In isolated rat liver lysosomes not only hsc73 (Figure 4F, lane 2) but also lgp96 (Figure 4F, lane 4) was coimmunoprecipitated with Ikappa B. These results together suggest that, at least in vitro, the direct transport of Ikappa B through the lysosomal membrane requires most of the components of the hsc73-mediated system.

To determine whether the lysosomal degradation of Ikappa B in living cells is mediated by the selective lysosomal pathway, we analyzed the effect that an increase in the activity of this pathway has on Ikappa B uptake and degradation. We have previously demonstrated that an increase in the lysosomal levels of lgp96 results in an increased activity of the pathway (Cuervo and Dice, 1996). As shown in Figure 5A, lysosomes from CHO cells stably overexpressing lgp96 (twofold increase) show a significant increase in the uptake and degradation of GAPDH but not of a pool of cytosolic proteins, most of which are not substrates for this lysosomal pathway of proteolysis. Uptake and degradation of Ikappa B by those lysosomes was also increased (Figure 5A). Differences in degradation rates for Ikappa B among those groups of lysosomes were mainly due to differences in the protein transported, since endogenous levels of Ikappa B in lysosomes from transfected cells were significantly higher than in lysosomes from untransfected cells (Figure 5B). Lysosomal levels of hexokinase, a nonsubstrate for the hsc73-mediated pathway, were similar in the two groups analyzed.


View larger version (37K):
[in this window]
[in a new window]
 
Figure 5.   Effect of overexpression of lamp2 in CHO cells on the uptake and degradation of Ikappa B. (A) Proteolytic activity of lysosomes from transfected cells. Intact lysosomes isolated from nontransfected CHO cells or cells transfected with the cDNA for human lamp2 (LAMP2+) were incubated with radiolabeled GAPDH, GST-Ikappa B, or a pool of cytosolic proteins without additions or in the presence of hsc73 (10 µg/ml) and ATP (5 mM) (HSC + ATP) as labeled. Proteolysis rates were measured as described in MATERIALS AND METHODS. Values are the means ± SD of three different experiments. (B) Lysosomal levels of Ikappa B and hexokinase. Intact lysosomes (100 µg of protein) from the cells described in A were subjected to SDS-PAGE and immunoblot with a specific antibody against Ikappa B (top panel) or hexokinase (HEXK, bottom panel).

Role of Ubiquitination and Phosphorylation of Ikappa B in Its hsc73-mediated Transport into Lysosomes

As described above, Ikappa B undergoes phosphorylation and polyubiquitination under specific conditions, and polyubiquitination targets the proteins for degradation by the 26S proteasome complex. The presence of polyubiquitinated proteins bound to the lysosomal membrane and inside the lysosomal matrix has been reported previously (Lenk et al., 1992). To determine whether covalent binding of ubiquitin to Ikappa B was also necessary for its lysosomal uptake, we separately immunoprecipitated the Ikappa B in the lysosomal matrix and membrane. Using an antiubiquitin antibody, we further analyzed by immunoblot for the presence of ubiquitin in the Ikappa B immunoprecipitates. As shown in Figure 6A, this antibody recognized high molecular weight ubiquitinated complexes in cytosol and in lysosomal membranes and matrix not subjected to immunoprecipitation (lanes 1-3), but none of those high molecular weight complexes were detected in the Ikappa B immunoprecipitated from lysosomal membrane and matrix (lanes 5 and 6). Covalent binding of a single molecule of ubiquitin to Ikappa B is also not necessary for its lysosomal uptake because the immunoprecipitated Ikappa B was not recognized by the specific antibody against ubiquitin (lanes 5 and 6). Thus, ubiquitination seems to be unnecessary for the selective transport of Ikappa B to lysosomes because the Ikappa B located in the lysosomal matrix or associated with the lysosomal membrane is not ubiquitinated.


View larger version (68K):
[in this window]
[in a new window]
 
Figure 6.   Lysosome-associated Ikappa B is not ubiquitinated or phosphorylated. (A) Cytosol (100 µg of protein), lysosomal membranes, and lysosomal matrix (derived from 100 µg of lysosomal protein) were isolated as described in MATERIALS AND METHODS and then directly subjected to SDS-PAGE (lanes 1-3) or immunoprecipitated with a specific antibody against Ikappa B (lanes 4-9). Filters were immunoblotted with a specific antibody against ubiquitin (lanes 1-6) or against Ikappa B (lanes 7-9). (B) Homogenate and lysosomes isolated from WEHI231 cells stably transformed with a HA epitope-tagged SS32/36AA Ikappa B. Samples (50 µg of protein) were subjected to SDS-PAGE and immunoblot with a specific antibody against HA (lanes 1 and 2) or against Ikappa B (lanes 3 and 4). (C) Rat liver cytosol (isolated in the presence of phosphatase inhibitors, 100 µg of protein, lanes 1 and 2) or purified GST-Ikappa B (lanes 3-8) were treated with phosphatase as described in MATERIALS AND METHODS and then subjected to SDS-PAGE and immunoblot with a specific antibody against Ikappa B. Binding and uptake of phosphatase-treated and untreated GST-Ikappa B by isolated rat liver lysosomes (lanes 5-8) was analyzed as described in Figure 4A.

Phosphorylation of Ikappa B at serines 32 and 36 is required for its signal-induced degradation by the 26S proteasome (Alkalay et al., 1995; Scherer et al., 1995). To determine whether phosphorylation of those residues is also required for the lysosomal degradation of Ikappa B, we analyzed the lysosomal content of Ikappa B in WEHI231 cells stably transfected with a HA epitope-tagged S32/36A Ikappa B mutant. As shown in Figure 6B, the mutated Ikappa B can be detected inside lysosomes using a specific antibody against the HA tag (Figure 6B, lane 2). Levels of endogenous and mutated Ikappa B inside lysosomes correlate with their levels in the total homogenate, suggesting that both forms of Ikappa B are equally transported inside lysosomes (Figure 6B, lanes 3 and 4). Phosphorylation of Ikappa B on other residues also appeared not to be necessary for its lysosomal transport. When the fusion protein GST-Ikappa B used to analyze direct transport of Ikappa B into isolated lysosomes was pretreated with a phosphatase, we found no significant differences in the rates of Ikappa B binding or uptake by lysosomes (Figure 6C, compare lanes 5 and 6 and lanes 7 and 8).

Physiological Relevance of Ikappa B Degradation by the hsc73-mediated Lysosomal Pathway

The hsc73-mediated lysosomal pathway is activated during serum deprivation in cultured cells or prolonged starvation in animals. To analyze the participation of lysosomes in Ikappa B degradation, we compared the Ikappa B half-life in CHO cells in the presence or absence of serum and the effect of NH4Cl, a lysosomal inhibitor (Figure 7). Rates of degradation of Ikappa B were measured by radioactive labeling of CHO cells followed by immunoprecipitation of Ikappa B at different times. As shown in Figure 7A (top), we found a significant increase in Ikappa B degradation when serum was removed from the culture medium. No change in NF-kappa B degradation under conditions of serum deprivation were found (Figure 7A, bottom). In addition, when lysosomal degradation was partially inhibited by NH4Cl, a marked decrease in Ikappa B degradation was observed in the absence of serum (Figure 7B, left). Changes in Ikappa B degradation during serum removal are even more dramatic in cells overexpressing lamp2 when compared with normal cells (approximately 1.8 times faster) (Figure 7B, right). After determining Ikappa B degradation rates in three independent experiments similar to the ones described above (Figure 7C), we calculated that the half-life of intracellular Ikappa B in the presence of serum is 4.4 d and in the absence of serum is 0.9 d. When NH4Cl was added, the half-lives obtained were 3.0 and 3.3 d in the presence and absence of serum, respectively. No changes were detected in the degradation rates of NF-kappa B in the absence of serum when NH4Cl was added (our unpublished results). These results show that Ikappa B is more rapidly degraded during serum deprivation, a condition known to activate the hsc73-mediated selective lysosomal pathway. Furthermore, during serum deprivation, lysosomes are the major site for this accelerated degradation because treatment with NH4Cl results in more than 90% inhibition of the serum-regulated Ikappa B degradation.


View larger version (52K):
[in this window]
[in a new window]
 
Figure 7.   Intracellular degradation of Ikappa B and p65 under different conditions. Nontransfected CHO cells (A) or cells transfected with lamp2 as labeled (B) were radiolabeled with [35S]methionine/cysteine for 48 h as described in MATERIALS AND METHODS. After extensive washing, cells were kept in medium with serum (+serum) or without serum (-serum). At indicated times (A) or after 18 h (B), cells were subjected to immunoprecipitation with a specific antibody against Ikappa B (A, top panel, and B) or p65 (A, bottom panel). Immunoprecipitates were resolved by SDS-PAGE and gels were exposed in a PhosphorImager screen. In B (lanes 4), 15 mM NH4Cl was added to the medium during the chase period. (C) Average value of Ikappa B degradation rates of three different experiments similar to the one shown in A (left panel) and similar experiments performed in the presence of 15 mM NH4Cl (right panel). t1/2 were calculated from the formula t1/2 = ln2/degradation rate.

We also analyzed the degradation of Ikappa B after 2 h of radiolabeling to determine whether Ikappa B was degraded with single exponential kinetics or whether two different degradation patterns could be detected in CHO cells. After the short labeling, most of the radiolabeled Ikappa B was degraded in the first 40 min both in the absence and in presence of serum (Figure 8A). However, after long exposure of the fluorographies containing the immunoprecipitates, it was possible to detect a portion of Ikappa B that was slowly degraded in cells supplemented with serum (Figure 8B). That portion of Ikappa B was also detected in cells deprived of serum but its degradation was markedly faster (Figure 8B). When Ikappa B proteolytic rates were analyzed in three separate experiments, we observed a pool of Ikappa B with a very short-half life (39 and 25 min in the presence and in absence of serum, respectively) along with a second pool of Ikappa B with a half-life of 3 d or more. As shown in Figure 8A, during the first hour of chase the degradation of Ikappa B was slightly faster in the absence of serum than in the presence of serum, but differences in degradation were markedly higher during 6-30 h of chase (Figure 8B). The detectable serum-dependent increase in Ikappa B degradation in the first hour of chase was not altered by NH4Cl (our unpublished results), suggesting that this increase is not due to lysosomal proteolysis. Thus, only the degradation rates of the long-lived pool significantly increased in response to serum deprivation and only under those conditions was Ikappa B degradation inhibited by NH4Cl (Figure 7C).


View larger version (20K):
[in this window]
[in a new window]
 
Figure 8.   Two different pools of Ikappa B can be detected in CHO cells. Cells were radiolabeled and subjected to immunoprecipitation with anti-Ikappa B antibody as described in Figure 7, with the exception that radiolabeling was shortened to 2 h. (A) Quantification of levels of Ikappa B immunoprecipitated during 40 min of chase in three different experiments. (B) Quantification of levels of Ikappa B immunoprecipitated during 6-30 h of chase in three different experiments.

Finally, we analyzed the effect of the increase in lysosomal Ikappa B degradation on NF-kappa B activity using electrophoretic mobility shift assays with a radiolabeled probe containing the immunoglobulin kappa  enhancer NF-kappa B-binding site. In nuclear extracts from CHO cells, this probe bound to a high molecular weight complex identified with specific antibodies (our unpublished results) as the p65/p50 heterodimer of the NF-kappa B family (as labeled in Figure 9). In many of the nuclear preparations, the probe also specifically bound to a lower molecular weight complex identified as the p50/p50 homodimer of the NF-kappa B family. However, since this complex was not always detected, all of the quantification of data refer to the p65/p50 heterodimer. First of all, we observed a constitutive activation of NF-kappa B in CHO cells. When serum was removed for 16 h, there were no detectable changes in NF-kappa B activation. If anything, the levels of nuclear NF-kappa B were slightly decreased. However, nuclear levels of NF-kappa B in serum-supplemented cells overexpressing lamp2 were 3.5 times the levels in nontransfected cells (Figure 9A). Moreover, when serum was removed for 16 h, the difference between transfected and nontransfected cells was even higher (nuclear NF-kappa B was 5.6 times more in cells overexpressing lamp2). Transfection of cells with an empty expression vector did not modify nuclear levels of NF-kappa B. No significant differences in NF-kappa B activation in the presence or the absence of serum under those conditions were found for nontransfected cells. However, in nontransfected cells, when serum deprivation was prolonged to more than 2 d (Figure 9B, top panel), we detected a significant increase in NF-kappa B activation. This increase in NF-kappa B nuclear activity correlated well with a decrease in the cytosolic levels of Ikappa B in serum-deprived cells (Figure 9B, bottom panel). Interestingly, the pattern of NF-kappa B activation by prolonged serum deprivation showed certain cell-type specificity. For example, in human fibroblasts there was a rise and fall in nuclear NF-kappa B corresponding with a decrease and increase in levels of Ikappa B (Figure 9C, bottom panel). The serum-induced increase in nuclear NF-kappa B activity also started earlier but it lasted for a shorter time than in CHO cells (Figure 9C, top panel).


View larger version (57K):
[in this window]
[in a new window]
 
Figure 9.   Effect of overexpression of lamp2 and serum deprivation on NF-kappa B nuclear translocation. (A) Nuclear extracts were prepared from nontransfected CHO cells or cells transfected with lamp2 (LAMP2) or with an empty vector (vector) maintained in the presence (+S) or absence (-S) of serum for 16 h prior to harvesting. Analysis of NF-kappa B-binding activity was performed as described in MATERIALS AND METHODS. In lane 3, cells were stimulated with PMA for 6 h. Lane 8 shows a binding assay performed as in lane 7 but in the presence of an excess of unlabeled probe. Results similar to those in lane 8 were obtained when unlabeled probe was added in each of the conditions analyzed (our unpublished results). (B and C) CHO cells (B) or human fibroblasts (C) were maintained in the absence of serum for the indicated times, and after harvesting nuclear extracts and cytosolic fractions were prepared as described in MATERIALS AND METHODS. NF-kappa B activity in the nuclear extracts (top panel) was analyzed as above. Content of Ikappa B in the cytosolic fractions (middle panel) was detected by immunoblot with a specific antibody for Ikappa B. Bottom panel shows the densitometric quantification of three experiments similar to the ones shown the in top and middle panels.

We have previously described that the hsc73-mediated lysosomal pathway of protein degradation is already active in CHO cells after 16 h of serum deprivation, and its activity progressively increases with the starvation time (Cuervo and Dice, 1996). As we have shown before (Figure 7), it is possible to detect a significant increase in the degradation of intracellular Ikappa B after 12 h of serum deprivation, but we found increased NF-kappa B activity only after 2 d or more of starvation (Figure 9, B and C). However, the initial increased degradation of Ikappa B after serum removal clearly has an effect on the sensitivity of the NF-kappa B activation in response to several activating agents. Thus, in CHO cells deprived of serum for only 12 h, we were able to detect a consistent increase in the NF-kappa B response to PMA, LPS, IL-1, and TNF-alpha when compared with serum-supplemented cells (Figure 10).


View larger version (61K):
[in this window]
[in a new window]
 
Figure 10.   Effect of serum deprivation on the NF-kappa B response to different stimuli. CHO cells were maintained in the presence (serum+) or absence (serum-) of serum for 12 h. After that incubation, PMA (A), LPS (B), IL-1 (C), or TNF-alpha (D) was added to the culture medium at the indicated concentrations for 4 h. At the end of the incubation, cells were harvested and NF-kappa B activity was assayed in the nuclear extracts as described in MATERIALS AND METHODS. The right side of the figure corresponds to the densitometric quantification of nuclear levels of NF-kappa B in three or four different experiments similar to the ones shown here.

Targeting of Ikappa B to Lysosomes for Its Degradation

The exact mechanism that triggers Ikappa B and other substrates of the hsc73-mediated pathway for its degradation in lysosomes remains unclear. It is known that the NF-kappa B response can be inhibited by antioxidants (Baeuerle and Henker, 1994) that somehow suppress a reaction required for release of Ikappa B from NF-kappa B (Schreck et al., 1992). In addition, certain oxidized proteins are better substrates for the hsc73-mediated pathway (Cuervo and Knecht, unpublished results). To determine a possible role of reactive oxygen species in the lysosomal targeting of Ikappa B, we further analyzed the effect of PDTC, a known antioxidant, in the degradation of the long-lived pool of Ikappa B. As shown in Figure 11A, PDTC was able to inhibit the NF-kappa B response to agents such as IL-1 and H2O2 not only in the presence but also in the absence of serum in CHO cells. In the presence of PDTC, there is a decrease in the degradation rates of Ikappa B after serum removal, and this inhibitory effect in the Ikappa B degradation is proportional to the amount of PDTC added (Figure 11B, lanes 4-6). The fact that the addition of H2O2 to the incubation medium under conditions of serum deprivation markedly increase Ikappa B degradation (Figure 11C) also suggests the participation of reactive oxygen species in the targeting of Ikappa B to lysosomes in response to serum withdrawal.


View larger version (59K):
[in this window]
[in a new window]
 
Figure 11.   Reactive oxygen species and lysosomal targeting of Ikappa B. (A) CHO cells were maintained in the presence or absence of serum and 200 µM PDTC (as indicated) during 12 h. Four hours before harvesting, IL-1 (1 ng/ml) or H2O2 (250 µM) were added to some of the samples. NF-kappa B activity was measured in the nuclear extracts as described in MATERIALS AND METHODS. (B and C) CHO cells were radiolabeled and subjected to immunoprecipitation 10 h after labeling with an anti-Ikappa B antibody as described in Figure 7. Where indicated, PDTC (100 or 200 µM) or H2O2 (125 µM) was added to the incubation medium after the washing postlabeling. The percentage of living cells after the treatment, monitored by trypan blue staining, was comparable to untreated cells. Lanes 1 and 5 in C show initial levels of Ikappa B after labeling.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The inducible degradation of Ikappa B bound to NF-kappa B by the 26S proteasome is a well-characterized process that results in activation of NF-kappa B (van Antwerp and Verma, 1996). Although other proteolytic systems have been implicated in Ikappa B degradation under specific circumstances (see INTRODUCTION), there have been no published studies implicating lysosomes in Ikappa B degradation. In this work, we have identified in cultured cells a long-lived pool of Ikappa B that is more rapidly degraded in response to serum deprivation (Figure 7). This finding may explain why serum deprivation can activate NF-kappa B in several cell types in culture (Grimm et al., 1996; Figures 9 and 10).

The long-lived pool of Ikappa B might allow cells to increase NF-kappa B activity more slowly than by the proteasome pathway. In fact, NF-kappa B activity increases only after 2 d of serum deprivation (Figure 9). The long-lived pool of Ikappa B may consist of conformational variants or heteromeric assemblies that have buried signals for ubiquitination. Under conditions of serum deprivation, this long-lived Ikappa B might be modified to expose the putative KFERQ motif, leading to binding by hsc73 and to transport into lysosomes. Ubiquitination or phosphorylation of Ikappa B is not required for this lysosomal uptake (Figure 6).

The stimuli that determine Ikappa B interaction with hsc73 and its subsequent degradation by this selective lysosomal pathway remain unclear. It has been previously described that the heat shock response inhibits Ikappa B degradation (Wong et al., 1997); however, the hsc73 involved in the lysosomal transport is not the heat shock inducible form but its constitutively expressed family member. The trigger for Ikappa B recognition by hsc73 might be located in the Ikappa B molecule itself. Our studies with the antioxidant agent PDTC (Figure 11) indicate that oxidation of Ikappa B might play an important role in its lysosomal targeting under conditions of serum deprivation.

The lysosomal population isolated from rat liver has been previously well characterized and it mainly corresponds to primary lysosomes derived from hepatocytes with undetectable levels of autophagic vacuoles or multivesicular bodies (Aniento et al., 1993; Cuervo et al., 1994). Compared with liver, spleen has a very heterogenous cellular composition. However, the method that we used to isolate lysosomes allows separation of lysosomes that are mainly derived from lymphocytes (Bowers, 1974). In addition, lysosomes isolated from a lymphocyte cell line in culture (Jurkat cells) also contain Ikappa B (our unpublished results). The recovery of lysosomes from rat spleen was approximately 4%, a slightly lower value than from rat liver (5.5%; Cuervo et al., 1995a). The purity of both lysosomal preparations, determined by assaying activity of mitochondrial and cytosolic marker enzymes as possible contaminants, was very high (>99%).

The percentage of total intracellular Ikappa B detected in lysosomes from spleen (Figure 1) is only 1.0-1.5% of the total in homogenates. However, this value corresponds to a steady-state condition of import and degradation inside the lysosomal matrix. As shown in Figure 2, using rat liver lysosomes, once Ikappa B reaches the lysosomal matrix, it is rapidly degraded. This conclusion is also supported by the effect of leupeptin, a lysosomal inhibitor, on levels of lysosomal Ikappa B (Figure 2B). In those experiments, we found that approximately 0.4% of the total Ikappa B in liver was degraded in lysosomes per hour (see RESULTS, Lysosomal Degradation of Ikappa B). Based on that degradation rate and by applying the formula t1/2= ln2/degradation rate, we calculated that the half-life of Ikappa B due to lysosomal degradation is approximately 7 d. However, only 40% inhibition of lysosomal degradation has been reported after leupeptin injection into rats (discussed in Cuervo et al., 1995b). Therefore, the half-life of the Ikappa B that can be attributed to lysosomal proteolysis would be closer to the value of 4 d experimentally determined in CHO cells (Figure 7).

Several of the results presented here strongly implicate Ikappa B as a substrate for the hsc73-mediated pathway of lysosomal proteolysis: 1) the higher Ikappa B content in lysosomes active in the direct uptake of proteins (Figure 3); 2) the direct interaction of Ikappa B with the cytosolic hsc73 (Figure 4D) and with lgp96, the receptor at the lysosomal membrane (Figure 4C); 3) the direct transport in vitro of Ikappa B into isolated rat liver and CHO cell lysosomes (Figures 4A and 5A); 4) the ATP/hsc73 dependence of this transport (Figure 5A); 5) the competitive effect of other substrates of the hsc73-mediated pathway on Ikappa B lysosomal uptake (Figure 4B); 6) the serum-dependent activation of Ikappa B lysosomal degradation in cultured cells (Figure 7); and 7) the increase in Ikappa B lysosomal degradation in cells with an increased activity for the hsc73-mediated lysosomal pathway (Figures